Visionary Ventures
Venture capitalNewport Beach · Series A–Late Stage · 13 people tracked
Find your way into Visionary Ventures
332 people in our graph share verified history with the Visionary Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Visionary Ventures believes that better information produces better investments and superior returns. It builds an advantage by partnering with Key Opinion Leaders (KOLs), industry experts, and strategic acquirers who source, vet, and advocate deals through a peer-review process. Beyond returns, the firm prioritizes backing companies that serve unmet or underserved markets and create broader societal impact. It seeks visionary, proven entrepreneurs turning ideas into market-leading businesses, focusing on the Series A to commercialization phase with target investments of $5M to $15M.
Source: firm website, verified Aug 3, 2026.
Team · 13 people
from the firm's website
What they invest in
from 13 of 18 portfolio companiesBiotech ×9Healthtech ×8Medical Devices ×6AI & Machine Learning ×2Data & Infrastructure ×2Crypto & Web3 ×1Digital Health ×1Longevity ×1
HQs:United States×9
Investments · 18 tracked
founders shown can be your intro pathBy year:2023 · 12022 · 32020 · 15 dated
RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.
HealthtechMedical DevicesPasadena, US
Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(President, Chief Executive Officer & Director)Mark Wilterding(Chief Financial Officer)in
Co-investorsFlying L PartnersForesite CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalRA Capital+2 more
Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.
BiotechHealthtechMedical Devices
Bobak Azamian, MD, PhD(Founder)inBobak Azamian(President and Chief Executive Officer)inJeffrey Farrow(Chief Financial Officer and Chief Strategy Officer)Seshadri Neervannan(Chief Operating Officer)Aziz Mottiwala(Chief Commercial Officer)inDianne Whitfield(Chief Human Resources Officer)in
Co-investorsAPERTURE Venture PartnersFlying L PartnersFrazier Life SciencesVivo CapitalBain Capital Life SciencesRTW Investments L.P.+1 more
Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma.
BiotechHealthtechMedical DevicesElkins Park, US
Tsontcho Ianchulev(Executive Officer, Director)Sean Ianchulev(Founder & Chairman of the Board (CMO))inMichael Haydin(Executive Officer)
BoardJeffry K Weinhuff(Director)Farrell Tyson(Director)Stephen Bloch(Director)in
Co-investorsaMoonCanaan PartnersCivilization Ventures Management, LlcFemHealth VenturesJSD Capital, LLCUS Venture Partners
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)inDavid Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in
BoardAaron Fletcher(Director)in
Co-investorsExSight VenturesInvest MichiganNovartis Venture FundBios PartnersInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more
Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.
BiotechHealthtechMedical Devices
Co-investorsArboretum VenturesMaverick Ventures IsraelCatalio Capital ManagementJohnson & Johnson Innovation – JJDCLifeSci Venture PartnersSequoia Capital+1 more
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.
BiotechDigital HealthDel Mar, US
Patrick Johnson(Executive Officer, Promoter)inMary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)
Co-investorsLongitude CapitalRA Capital
Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease.
BiotechHealthtechMedical DevicesSeattle, US
DAVID ROSTOV(Executive Officer)inGREG KUNST(Executive Officer, Director)PATRICK LALLY(Director)JEANNETTE BANKES(Director)CHRISTINE MCCAULEY(Director)ARNAUD LACOSTE(Executive Officer)
Co-investorsDeerfield Management CompanyFlying L Partners
HealthtechReno, US
Tsontcho Ianchulev(Executive Officer, Director)Charles Warden(Director)Brian Walsh(Executive Officer, Director)Bruce J. Brumfield, Jr.(Director)Glenn Rockman(Director)inJim Mazzo(Director)
Co-investorsVisionary Venture
Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.
BiotechHealthtechLongevity
William Lowry(PhD)inChristina Weng(Chief Medical Officer)inNathan Wheeler(Chief Operating Officer)in
BoardDaniel Gil(PhD)
Co-investorsGV (Google Ventures)ARCH Venture PartnersHAWKTAILYK Bioventures
BiotechCopley, US
Kevin Hershfield(Executive Officer, Director)
BoardWilliam Link(Director)Jeffry Weinhuff(Director)Tyler Stowater(Director)Richard Heinick(Director)Steve Pazol(Director)
Co-investorsFlying L PartnersVersant Venture AIV HoldingsVisionary Venture
Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.
AI & Machine LearningData & Infrastructure
Art Abal(Founder)
Co-investorsAbstract VenturesAlphaLab CapitalCaladanEarl Grey CapitalParadigmSCB 10X+7 more
Vana provides open data infrastructure for AI that lets individuals control the data they create and choose how it is used.
AI & Machine LearningCrypto & Web3Data & Infrastructure
Co-investorsFlori VenturesBoxGroupCoinbase VenturesDeFiance CapitalExSight VenturesGSR+7 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CorneagenPelage PharmaceuticalsRe-vanaSurface Pharmaceuticals, Inc.Zeptozone
Exits · 2
2 IPOsRxsightNASDAQ: RXSTTarsus PharmaceuticalsNASDAQ: TARS
Portfolio news
latest coverage across their companiesVana · ophthalmologytimes.com · Sep 1, 2026
Tarsus Pharmaceuticals · americanbankingnews.com · Aug 28, 2026
Aurion Biotech · regmednet.com · Aug 20, 2026
Rxsight · tipranks.com · Aug 12, 2026
Pelage · hairlosscure2020.com · Jul 26, 2026
Pelage Pharmaceuticals · hairlosscure2020.com · Jul 26, 2026
Iantrek · finsmes.com · Apr 29, 2026
Frequently asked questions
- How many investments has Visionary Ventures made?
- Visionary Ventures has 18 tracked investments, 2 of which have exited.
- What stage does Visionary Ventures invest at?
- Visionary Ventures invests at the Series A, Series B, Growth, Late Stage stages.
- What is Visionary Ventures's typical check size?
- Visionary Ventures typically writes checks of $5M – $15M.
- What sectors does Visionary Ventures focus on?
- Visionary Ventures focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices, Sector Agnostic.
- Where is Visionary Ventures located?
- Visionary Ventures is headquartered in Newport Beach, US.
- Who does Visionary Ventures co-invest with?
- Visionary Ventures most often shares deals with Flying L Partners, ExSight Ventures, Longitude Capital, among 26 tracked co-investors.
Similar investors
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Claret Capital Partners is a European venture debt provider that finances technology, life sciences and impact companies, having deployed over €1.5bn across more than 200 companies.